Roche expands hepatitis C deal with Merck after Victrelis' EU nod
This article was originally published in Scrip
Executive Summary
Roche and Merck have expanded their landmark deal to commercialise the new hepatitis C treatment Victrelis (boceprevir) to include Europe, following the product's approval by the EMA earlier this week.